ArticleIndian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine2026
Gastrointestinal Tolerance to
Article in Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Diarrhea is common in critically ill patients receiving enteral nutrition and often leads to feed interruption. Arrowroot ( Patients and methods: A nonrandomized controlled open labeled, quasi-experimental, posttest-only trial was conducted in intensive care unit (ICU) patients receiving nasogastric enteral feeding. The intervention group received 100 gm of arrowroot powder added to formula feeds for 5 days; controls received standard formula feeds. Gastrointestinal intolerance to the specified weight of arrowroot powder was observed as incidence of new-onset noninfectious diarrhea, vomiting, and abdominal distension. Clinical outcomes included hospital-acquired infections, ICU/hospital length of stay (LOS) and ICU mortality. Results: Ninety-four patients were included (34 intervention, 60 control). Arrowroot supplementation was well tolerated, with no adverse GI effects. New-onset diarrhea was lower in the intervention group (8.8 vs 26.7%), though not statistically significant. Relative risk reduction was 0.67. No differences in nosocomial infections, mortality, or LOS were observed. Conclusion: Arrowroot supplementation in enteral feeds appears feasible and, safe in critically ill patients. Its potential as a supplement to enteral feeds to reduce diarrhea needs to be explored with larger studies. How to cite this article: Mathew M, Verghese S. Gastrointestinal Tolerance to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.